Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsed, Refractory Multiple Myeloma”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Study completedNCT03544281
What this trial is testing

To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 153
Early research (Phase 1)Ended earlyNCT00963495
What this trial is testing

Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphocytic LeukemiaChronic Lymphocytic Leukemia+4 more
University Health Network, Toronto 11
Testing effectiveness (Phase 2)Looking for participantsNCT05922501
What this trial is testing

Isatuximab, Bela Maf, Pom, and Dex in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Relapsed CancerRefractory Multiple MyelomaMultiple Myeloma
Massachusetts General Hospital 50
Testing effectiveness (Phase 2)Ended earlyNCT00985907
What this trial is testing

Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple MyelomaPatient Participation
University of California, San Francisco 13
Testing effectiveness (Phase 2)Study completedNCT00315757
What this trial is testing

Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Human Genome Sciences Inc. 105
Testing effectiveness (Phase 2)Study completedNCT01913730
What this trial is testing

Maintenance Therapy With Subcutaneous Bortezomib

Who this might be right for
Multiple Myeloma
European Myeloma Network B.V. 63
Testing effectiveness (Phase 2)Ended earlyNCT01116232
What this trial is testing

Sirolimus, Tacrolimus, Thymoglobulin and Rituximab as Graft-versus-Host-Disease Prophylaxis in Patients Undergoing Haploidentical and HLA Partially Matched Donor Hematopoietic Cell Transplantation

Who this might be right for
Chronic Myeloproliferative DisordersGraft Versus Host DiseaseLeukemia+5 more
Barbara Ann Karmanos Cancer Institute 4
Early research (Phase 1)UnknownNCT04706936
What this trial is testing

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Second Affiliated Hospital, Zhejiang University, School of Medicine 25
Early research (Phase 1)Ended earlyNCT00243763
What this trial is testing

TKI258 in Subjects With Refractory or Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Novartis 64
Large-scale testing (Phase 3)Looking for participantsNCT05519085
What this trial is testing

Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

Who this might be right for
Relapsed or Refractory Multiple Myeloma
Celgene 810
Very early researchLooking for participantsNCT06045091
What this trial is testing

To Evaluate the Safety and Efficacy of Human BCMA Targeted CAR-NK Cells Injection for Subjects With R/R MM or PCL

Who this might be right for
Multiple MyelomaPlasma Cell Leukemia
Hrain Biotechnology Co., Ltd. 18
Early research (Phase 1)Ended earlyNCT04401020
What this trial is testing

First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL

Who this might be right for
Neoplasm Malignant
Sanofi 47
Not applicableNo Longer AvailableNCT00063791
What this trial is testing

Assess Two Different Strategies of Combining Dexamethasone and VELCADE

Who this might be right for
Multiple Myeloma
Millennium Pharmaceuticals, Inc.
Not applicableLooking for participantsNCT06485076
What this trial is testing

Early Palliative Care for Patients With Multiple Myeloma and Aggressive Lymphoma

Who this might be right for
Multiple Myeloma in RelapseMultiple Myeloma, RefractoryMultiple Myeloma Stage III+5 more
University Health Network, Toronto 144
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Early research (Phase 1)Looking for participantsNCT06153251
What this trial is testing

Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

Who this might be right for
Relapsed and/or Refractory Multiple Myeloma
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 187
Early research (Phase 1)Looking for participantsNCT07075185
What this trial is testing

Evaluate a Novel Gene Therapy in Patients With Relapsed and Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseMyeloma MultipleMultiple Myeloma Progression+11 more
Kelonia Therapeutics, Inc. 70
Early research (Phase 1)Active Not RecruitingNCT06425991
What this trial is testing

A Study Comparing Pre- and Post-Change Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Janssen Research & Development, LLC 108
Testing effectiveness (Phase 2)Study completedNCT03860038
What this trial is testing

TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma in RelapseRefractory Multiple Myeloma
TJ Biopharma Co., Ltd. 113
Not applicableApproved For MarketingNCT01632826
What this trial is testing

Pomalidomide (POM) in Combination With Low Dose Dexamethasone (LD-Dex) in Patients With Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Celgene
Next Page